Document is current
Any future updates will be listed below
-
Authors
Ye, Youqiong https://orcid.org/0000-0001-8332-4710
Jing, Ying
Li, Liang
Mills, Gordon B. https://orcid.org/0000-0002-0144-9614
Diao, Lixia https://orcid.org/0000-0001-6995-4492
Liu, Hong https://orcid.org/0000-0001-9976-2985
Han, Leng https://orcid.org/0000-0002-7380-2640
-
Funding
Funding for this research was provided by:
Cancer Prevention and Research Institute of Texas (RR150085)
- License Information
-
More Information
Article History
Received: 11 November 2019
Accepted: 24 March 2020
First Online: 14 April 2020
Competing interests
: G.B.M. has sponsored research support from AstraZeneca, Critical Outcomes Technology, Karus, Illumina, Immunomet, Nanostring, Tarveda and Immunomet and is on the Scientific Advisory Board for AstraZeneca, Critical Outcomes Technology, ImmunoMet, Ionis, Nuevolution, Symphogen and Tarveda. All other authors declare no competing interests.
